News Releases

As former CEO of Seattle biotech Dendreon Corp. Mitchell Gold embarks on a new biotech immunotherapy company called Alpine Immune Sciences Inc. , how will he ensure it doesn’t meet the same fate as his prior company? Gold led Dendreon for nine years and stepped down in 2012.

Dendreon may be on its last legs , but former CEO Mitchell Gold is happily entrenched in other projects: He’s launching a next-generation immunotherapy startup called Alpine Immune Sciences , seeding about $1.3 million into the company through his investment firm, Alpine BioVentures .